You searched for "clinic"
Management of patulous eustachian tube dysfunction
Idiopathic sudden sensorineural hearing loss (iSSNHL) is defined as a hearing loss of 30 dB or more at three contiguous frequencies within 72 hours, with acute low-tone hearing loss (ALHL) excluded from this category. Despite standard treatment, outcomes vary: one-third...
Auditory processing disorder (APD): knowledge and practice in hearing healthcare
Awareness and practice for children and adults presenting with APD is variable across healthcare practice. Recently reported experiences of individuals and their families affected by APD show difficulty accessing referral and overall lack of recognition, and note that audiologists show...
Association of tinnitus with dementia
In this large case-controlled study, the authors have compared the presence of tinnitus prior to the diagnosis of dementia in the study group with those without dementia. Dementia patients were selected from the National Health Insurance group. The control group...
Not the answer yet, but it may be in the future
AI is certainly a topical issue these days and radiomics refers to techniques which allow the extraction of quantitative features from medical imaging to produce large data sets for clinical problem solving. This paper looks at CT imaging of the...
Cognitive development in children with cochlear implants
This systematic review investigates the comparative cognitive outcomes in children using bilateral versus unilateral cochlear implants, as well as those using cochlear implants versus hearing aids. The review synthesises findings from 30 studies involving a total of 11,986 children and...
What are the consequences of facial palsy on working life?
Facial palsy (FP) has multiple causes, including iatrogenic or idiopathic paralysis, trauma and tumours. Whilst for certain aetiologies, such as Bell’s palsy, recovery of function is expected, many patients will experience permanent symptoms due to incomplete recovery of the facial...
Eosinophilic complications during dupilumab therapy
Dupilumab is a humanised monoclonal antibody that targets type 2 inflammation by blocking IL-4 and IL-13 signalling. Reported adverse events from its use include injection site erythema, conjunctivitis, arthralgia and hypereosinophilia. The potential for more severe eosinophilic-related complications such as...
